| |
sensitivity
|
95% CI
|
specificity
|
95% CI
|
+LR
|
95% CI
|
-LR
|
95% CI
|
|---|
|
anti-GP2 IgA
|
13.0
|
8.3–19.0
|
98.0
|
93.0–99.8
|
6.6
|
1.6–27.4
|
0.9
|
0.8–1.0
|
|
anti-GP2 IgG
|
28.4
|
21.7–35.8
|
92.2
|
85.1–96.6
|
3.6
|
1.8–7.3
|
0.8
|
0.7–0.9
|
|
anti-GP2 IgA or IgG
|
30.2
|
23.4–37.7
|
91.2
|
83.9–95.9
|
3.4
|
1.8–6.6
|
0.8
|
0.7–0.9
|
|
ASCA IgA
|
23.1
|
17.0–30.2
|
97.1
|
91.6–99.4
|
7.8
|
2.5–24.7
|
0.8
|
0.7–0.9
|
|
ASCA IgG
|
28.4
|
21.7–35.8
|
95.1
|
88.9–98.4
|
5.8
|
2.4–14.1
|
0.8
|
0.7–0.8
|
|
ASCA IgA or IgG
|
35.5
|
28.3–43.2
|
93.1
|
86.4–97.2
|
5.2
|
2.5–10.9
|
0.7
|
0.6–0.8
|
|
PAB ≥1/20
|
45.4
|
37.6–53.4
|
76.5
|
67.0–84.3
|
1.9
|
1.3–2.8
|
0.7
|
0.6–0.8
|
|
PAB ≥1/40
|
38.5
|
31.1–46.2
|
79.4
|
70.3–86.8
|
1.9
|
1.2–2.9
|
0.8
|
0.7–0.9
|
|
at least 1 ab*
|
50.9
|
43.1–58.6
|
85.3
|
76.9–91.5
|
3.5
|
2.1–5.6
|
0.6
|
0.5–0.7
|
|
at least 2 ab*
|
27.2
|
20.7–34.6
|
97.1
|
91.6–99.4
|
9.2
|
3.0–29.0
|
0.8
|
0.7–0.8
|
|
at least 3 ab*
|
10.6
|
6.4–16.3
|
100.0
|
96.4–100.0
|
∞
| |
0.9
|
0.8–0.9
|
|
at least 4 ab*
|
4.1
|
1.7–8.3
|
100.0
|
96.4–100.0
|
∞
| |
1.0
|
0.1–1.0
|
- Sensitivity, specificity and likelihood ratios were calculated using a cut-off of 20 U/ml for all ELISA and a titre of 1/20 and 1/40 of IIF.
- ab, antibody; ASCA, antibody to mannan of Saccharomyces cerevisiae; CD, Crohn’s disease; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; GP2, zymogen granule membrane glycoprotein 2; LR, likelihood ratio; PAB, pancreatic autoantibody; UC, ulcerative colitis; *anti GP2 and/ or ASCA.
